Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S458000, C514S460000
Reexamination Certificate
active
07074825
ABSTRACT:
A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.
REFERENCES:
patent: 6133312 (2000-10-01), Elson
patent: 6251400 (2001-06-01), Guthrie et al.
patent: 2004/0110848 (2004-06-01), Peffley et al.
Cecil Textbook of Medicine, 21st Edition, vol. 1, published 2000 by W.B. Saunders Company (PA), pp. 1060-1074.
McAnally, Jennifer A. [M.S.]; Mo, Huanbio [advisor], “Potentiation of the Chemotherapeutic Action of Low-Dose Lovastatin with Genistein and gamma-2-Tocotrienol Demonstrated in Human Prostate and Lung Tumor Cells and Murine Melanoma Cells”, Masters Abstract International, (2003) vol. 42, No. 4, p. 1199. Order No. AAI1427573, 50 pages.
Bravo, Lou [Ph.D.]; Hsueh, Andie [advisor], “The Growth-Suppressive Effects of Farnesol, gamma-Tocotrienol, Genistein, Lovastatin and Pomegranate Extracts Individually and in Combinations on Human Prostate Tumor Cells”, Dissertation Abstracts International, (2003), vol. 64, No. 11B, p. 5455, Order No.: AAI3114311. 71 pages.
Abid Mr, Li Y, et al. (1999)“Translational rregulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein . . . ” J Biol Chem; 274(50): 35991-8.
Agarwal R. (2000)“Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.” Biochem Pharmacol;60(8): 1051-9.
Alhasan SA, Aranha O, Sarkar FH. (2001) Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res; 7(12): 4174-81.
Asslan R, Pradines A, et al. (1998) “Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA . . . ” Biochem J; 330 ( Pt 1): 241-6.
Azrolan NI, Coleman PS. (1989) “A discoordinate increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase . . . ” Biochem J; 258(2): 421-5.
Brown MS, Goldstein JL. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell; 89(3): 331-40.
Chen Y, Hughes-Fulford M. (2001) “Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor . . . ” Int J Cancer; 91(1): 41-5.
Coleman PS, Chen LC, Sepp-Lorenzino L. (1997) Cholesterol metabolism and tumor cell proliferation. Subcell Biochem; 28: 363-435.
Constantinou A, Huberman E. (1995) “Genistein as an inducer of tumor cell differentiation: possible . . . ” Proc Soc Exp Biol Med; 208(1): 109-15.
Correll CC, NG L, Edwards PA. (1994) “Identification of farnesol as the non-sterol derivative of mevalonic acid required . . . ”. J Biol Chem; 269(26): 17390-3.
Coxon FP, Helfrich MH,et al (2001) “Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl . . . ” J Biol Chem; 276(51): 48213-22.
Elson CE. (1995) “Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer . . . ” J Nutr; 125(6 Suppl): 1666S-1672S.
Elson CE, Peffley DM, et al.(1999) “Isoprenoid-mediated inhibition of mevalonate synthesis: potential . . . ” Proc Soc Exp Biol Med; 221(4): 294-311.
Engfelt WH, Shackelford JE, et al (1997) “Characterization of UT2 cells. The induction of peroxisomal . . . ” J Biol Chem; 272(39): 24579-87.
Engstrom W, Schofield PN. (1987) “Expression of the 3-hydroxy-3-methylglutaryl coenzyme A-reductase alnd LDL-receptor . . . ” Anticancer Res;(3 Pt B): 337-42.
Ericsson J, Jackson SM, et al (1996) “Sterol regulatory element binding protein binds to a cis element in the promotor . . . ” Proc Natl Acad Sci U S A; 93(2): 945-50.
Ericsson J, Usheva A, Edwards PA. (1999) “YY1 is a negative regulator of transcription of three sterol regulatory . . . ” J Biol Chem; 274(20): 14508-13.
Fournier DB, Erdman JW, JR., et al.(1998) “Soy, its components, and cancer prevention: a review . . . ” Cancer Epidemiol Blomarkers Prev; 7(11): 1055-65.
Fritz T, Buechler, R. et al (1998) “Translational efficiency of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) . . . ” Circ Res; 98: 379.
Gayen AK, Peffley DM. (1995) “The length of 5′-untranslated leader sequences influences distribution of . . . ” Arch Biochem Biophys; 322(2): 475-85.
Gardner RG, Shearer AG, et al (2001) “In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic . . . ” Mol Cell Biol; 21(13): 4276-91.
Goldstein JL, Brown MS. (1990) Regulation of the mevalonate pathway. Nature: 343(6257): 425-30.
Guan G, Jiang G, et al. (1995) Molecular cloning and functional analysis of the promoter of the human squalene synthase gene. J Biol Chem; 270(37): 21958-65.
Hentosh P, Yuh SH, et al. (2001) Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog; 32(3): 154-66.
Hotz MA, Gong J. Traganos F, Darzynkiewicz Z. (1994) “Flow cytometric detectioin of apoptosis: comparison . . . ” Cytometry; 15(3): 237-44.
Jackson RJ, Wickens M. (1997) Translational controls impinging on the 5′-untranslated region and initiation factor proteins. Curr Opin Genet Dev; 7(2): 233-41.
Jiang Y, Muschel RJ. (2002) Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res; 62(6): 1910-4.
Jirtle RL, Haag JD, et al. (1993) “Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta . . . ” Cancer Res; 53(17): 3849-52.
Jones RM, Branda J,et al (1996) “An essential E box in the promoter of the gene encoding the mRNA cap-binding protein . . . ” Mol Cell Biol; 16(9): 4754-64.
Kelloff GJ, Fay Jr, et al. (1996) “Epidermal growth factor receptor kinase inhibitors as potential . . . ” Cancer Epidemiol Biomarkers Prev; 5(8): 657-66.
Kevil CG, DE Benedetti A, et al. (1996) “Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: . . . ” Int J Cancer; 65(6): 785-90.
Knight JB, Cao KT, et al. (2000) “Expression of a prenylation-deficient Rab4 interferes with propagation of insulin signaling through . . . ” Endocrinology; 141(1): 208-18.
Kotzka J, Muller-Wieland D, et al. (2000) “Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade.” J Lipid Res; 41(1): 99-108.
Levitzki A, Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science; 267(5205): 1782-8.
LI BD, Liu L, Dawson M OE Benedetti A. (1997) Overexpression of eukaryotic initiation factor 4E (elF4E) in breast carcinoma. Cancer; 79(12): 2385-90.
LI S, Sonenberg N, et al. (2002) “Translational control of cell fate: availability of phosphorylation sites on translational . . . ” Mol Cell Biol; 22(8): 2853-61.
Liu JF, Crepin M, Liu JM. et al. (2002) “FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through . . . ” Biochem Biophys Res Commun; 296(4): 1174-82.
Lopez JM, Bennett MK, et al (1996) “Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control . . . ” Proc Natl Acad SCi U S A; 93(3): 1049-53.
M
Elson Charles E.
Hentosh Patricia M.
Mo Huanbiao
Peffley Dennis M.
Henley III Raymond J.
Thompson Loren K.
LandOfFree
Composition and method for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531708